
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences is a global commercial-stage biotechnology company that specializes in virology and infectious disease, although it’sbecoming a bigger player in the oncology space and has built out a deep pipeline across oncology and virology. The recent FDA acceptance of 300 mg QW oral Yeztugo (NDA expected by Feb 2027), along with stronger-than-expected uptake of Yeztugo among PrEP-naive patients, bodes well for continued growth in this franchise and sets up for Gilead to offer multiple dosing options under a single brand, enhancing its commercial narrative and market position. Gilead also holds potential for meaningful near-term growth from its CAR-T cell therapy anito-cel, with initial revenues expected in 1Q27 and potential for expansion into earlier lines of therapy. Overall, Gilead's solid performance across key products, coupled with its commitment to sustainability and transparency, make it a strong investment opportunity.
Bears say
Gilead Sciences is one of the leaders in the biotech industry, with a strong track record of successfully navigating through patent cliffs. Their current portfolio includes blockbuster drugs in the HIV and hepatitis B and C markets, with potential for growth in the oncology field through strategic acquisitions and partnerships. While concerns about PrEP persistence have caused the stock to underperform in the short term, the company's strong financials and pipeline optionality make it a compelling long-term investment opportunity.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares